Inclusion Criteria:

- Patients who were diagnosed by the histologic, cytologic diagnosis of IV non-small
cell lung cancer

- Age from 18 to 70 years old

- At least one target lesion diameter spiral CT ≥ 1 cm, or the common CT ≥ 2 cm, and
can be measured by imaging tools

- ECOG 0-1

- Expected life time longer than 12 weeks

- Normal laboratory values:

leucocyte≥ 4×109/L neutrophil≥ 1.5×109/L platelet≥100×109/L Hemoglobin≥ 10g/L ALT and AST
≤2.5×ULN (≤5×ULN if liver metastasis)

Exclusion Criteria:

- Patients have not used drugs according to protocol

- Patients were allergic to pemetrexed or cisplatin

- Patients received radiotherapy or other biological treatment 4 weeks before the trial

- Uncontrolled hydrothorax or hydropericardium

- neuropathy toxicity ≥ CTC 3

- Severe symptomatic heart disease

- Active upper gastrointestinal ulcer or digestive disfunction

- Severe infection or metabolic disfunction

- Patients with other malignant tumor

- Uncontrolled brain metastases

- Patients have accepted other clinical trials

- Female patients during their pregnant and lactation period, or patients without
contraception